Merck, Ridgeback says COVID-19 pill molnupiravir shows antiviral activity against omicron variantMarket Watch • 01/28/22
Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro StudiesBusiness Wire • 01/28/22
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following SurgeryBusiness Wire • 01/27/22
Britain needs 6,000 more volunteers to take Merck's COVID-19 pill mainstreamProactive Investors • 01/25/22
Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized PatientsBenzinga • 01/24/22
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of MedicineBusiness Wire • 01/20/22
Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory TrialBenzinga • 01/19/22
Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With SorafenibBusiness Wire • 01/18/22